New drug combo hopes to ease myelofibrosis symptoms

NCT ID NCT05371964

Recruiting now Disease control Sponsor: Geron Corporation Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 31 times

Summary

This early-phase study tests a new drug (imetelstat) added to the standard treatment (ruxolitinib) for people with myelofibrosis, a rare bone marrow cancer. The goal is to find the best dose and see if the combination safely reduces symptoms like fatigue and spleen discomfort. About 36 adults with intermediate or high-risk disease are being enrolled.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

City of Hope
RECRUITING

Duarte, California, 91010, United States
City of Hope
RECRUITING

Irvine, California, 92618, United States
Fred Hutchinson Cancer Center
RECRUITING

Seattle, Washington, 98109, United States
H. Lee Moffitt Cancer Center and Research Institute, Inc.
RECRUITING

Tampa, Florida, 33612, United States
Icahn School of Medicine at Mount Sinai
RECRUITING

New York, New York, 10029, United States
Texas Oncology
WITHDRAWN

Denison, Texas, 75020, United States
Texas Oncology
WITHDRAWN

Tyler, Texas, 75702, United States
University of Miami
RECRUITING

Coral Gables, Florida, 33146, United States

Conditions

Explore the condition pages connected to this study.

MYELOFIBROSIS